Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Modified DCF in Gastroesophageal Adenocarcinoma
NCT00390416Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2006
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in gastroesophageal adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT00390416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390416.